Mocravimod - Priothera
Alternative Names: KRP-203Latest Information Update: 08 Dec 2023
Price :
$50 *
At a glance
- Originator Kyorin Pharmaceutical
- Developer Kyorin Pharmaceutical; Novartis; Priothera
- Class Anti-inflammatories; Propylene glycols
- Mechanism of Action Sphingosine 1 phosphate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Crohn's disease; Cutaneous lupus erythematosus; Ulcerative colitis
Highest Development Phases
- Phase III Acute myeloid leukaemia
- Phase II Crohn's disease; Cutaneous lupus erythematosus; Ulcerative colitis
- Phase I/II Diffuse large B cell lymphoma
Most Recent Events
- 27 Nov 2023 Mocravimod receives Orphan Drug status for improvement of the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies in USA
- 05 Jun 2023 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater) in Germany (PO) (EudraCT2022-003618-35)
- 10 Apr 2023 Mocravimod - Priothera is available for licensing as of 10 Apr 2023. info@priothera.com